Copaxone 40mg Generic At-Risk Launch Anticipated As Soon As February

Teva is seeking injunction to block generic entry after court rules four patents on the three-times-a-week dosage are invalid; analysts expect launch soon after FDA approves an ANDA, with Sandoz/Momenta generic the likely leader.

chess

Teva Pharmaceutical Industries Ltd. is expected to soon face generic competition for its thrice weekly Copaxone (glatiramer) multiple sclerosis drug since a district court found four patents on the product to be invalid.

On Jan. 30, Delaware US District Court Judge Gregory Sleet issued a judgement that the patents on the 40mg dose...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet